首页 › 基金 › a16z Capital Management, L.L.C. › SYRE
a16z Capital Management, L.L.C. 对 SYRE 的持仓历史
SPYRE THERAPEUTICS INC · 医疗保健
a16z Capital Management, L.L.C. 在 Q3 2026 的 13F 申报中披露持有 SYRE(SPYRE THERAPEUTICS INC)3,082,725 股,市值约 US$56.7M,约占其申报组合的 0.29%,在其申报持仓中市值排名第 6 位。 a16z Capital Management, L.L.C. 于 Q3 2026 首次申报该持仓。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
a16z Capital Management, L.L.C. 对 SYRE 的持仓演变
a16z Capital Management, L.L.C. 于 Q3 2026 首次披露 SYRE 持仓:3,082,725 股(约 US$56.7M)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2026 | 3.08M | $56.74M | 新进 |
关于 SYRE 与 13F 数据
SYRE(SPYRE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 68 只申报持有 SYRE,申报仓位最大的包括:Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 SYRE 的基金
- Paradigm Biocapital Advisors LP 4.46M 股 · $396.85M · Q3 2026
- RTW INVESTMENTS, LP 3.69M 股 · $328.68M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.20M 股 · $309.04M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M 股 · $245.76M · Q3 2026
- Venrock Adviser, LLC 2.49M 股 · $221.28M · Q3 2026
- TCG Crossover Management, LLC 1.90M 股 · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M 股 · $168.46M · Q3 2026
- Affinity Asset Advisors, LLC 1.28M 股 · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M 股 · $103.33M · Q3 2026
- Siren, L.L.C. 868.60K 股 · $77.33M · Q3 2026
- BRAIDWELL LP 713.96K 股 · $63.56M · Q3 2026
- Commodore Capital LP 700.00K 股 · $62.32M · Q3 2026
更多关于 a16z Capital Management, L.L.C.
常见问题
How long has a16z Capital Management, L.L.C. held SYRE?
a16z Capital Management, L.L.C. has disclosed SYRE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is a16z Capital Management, L.L.C.'s current position in SYRE?
As of Q3 2026, a16z Capital Management, L.L.C. holds 3.08M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $56.74M, representing 0.29% of its reported portfolio and ranking #6.
Has a16z Capital Management, L.L.C. been buying or selling SYRE?
In the latest 13F filing (Q3 2026), a16z Capital Management, L.L.C. newly opened its position in SYRE.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.